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Summary
 
Antigen-specific B cells are implicated as antigen-presenting cells in memory and tolerance re-
sponses because they capture antigens efficiently and localize to T cell zones after antigen cap-
ture. It has not been possible, however, to visualize the effect of specific B cells on specific
CD4
 
1
 
 helper T cells under physiological conditions. We demonstrate here that rare T cells are
activated in vivo by minute quantities of antigen captured by antigen-specific B cells. Antigen-
activated B cells are helped under these conditions, whereas antigen-tolerant B cells are killed.
The T cells proliferate and then disappear regardless of whether the B cells are activated or tol-
erant. We show genetically that T cell activation, proliferation, and disappearance can be medi-
ated either by transfer of antigen from antigen-specific B cells to endogenous antigen-present-
ing cells or by direct B–T cell interactions. These results identify a novel antigen presentation
route, and demonstrate that B cell presentation of antigen has profound effects on T cell fate
that could not be predicted from in vitro studies.
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A
 
variety of both beneficial and pathological immune re-
sponses involve B cell presentation of antigen to Ths.
Memory B cells carry high affinity B cell receptors (BCRs)
 
1
 
that allow them to concentrate trace amounts of antigen
and these cells often localize to sites of antigen entry or fil-
tering, such as beneath the mucosal epithelia and the
splenic marginal zone (1, 2). Once they bind antigen, they
rapidly move to the T cell zones of the spleen and lymph
node, where there is a large traffic of recirculating T cells
(1). Similarly, self-reactive B cells are concentrated in the T
zones as a result of binding autoantigens (3–6). Once lo-
cated in this site, memory B cells which present foreign an-
tigens to Ths proliferate and produce antibody, whereas
self-reactive B cells that present self-antigens are killed by
Ths expressing Fas ligand (7, 8). Although the outcome of
these B–T cell interactions is known for the B cell, it is not
known if the Th is primed, proliferates, or is tolerized, and
how B cell presentation may impact regulatory phenomena
such as immune deviation in allergy or epitope spreading in
autoimmunity.
In vitro studies have shown that activated, antigen-spe-
cific B cells present antigen to T cells and trigger prolifera-
tion and lymphokine secretion, although this presentation
may be less efficient than presentation by activated den-
dritic cells (9–12). By contrast with activated B cells, pre-
sentation of antigen by tolerant B cells does not induce T
cell proliferation and lymphokine secretion in vitro, due to
deficient expression of, and costimulation by, B7.2 (13).
Based upon in vitro studies with T cell clones, presentation
of antigen by costimulation-deficient cells might be pre-
dicted to induce a state of T cell anergy (14–16).
B cells have been shown to be tolerogenic for T cells in
vivo, but it remains unclear whether the basis for tolerance
lies in T cell deletion, anergy, or other regulatory processes
(17–22). It has been suggested that B cells cannot activate T
cells in vivo, but rather induce a state of anergy (17, 21,
23–25). Studying the fate of helper T cells after B cell anti-
gen presentation in vivo represents a substantial technical
challenge. Approaches that use irradiated or lymphocyte-
deficient mice as vessels to track specific cells produce in-
flammatory conditions or disrupted lymphoid microenvi-
ronments that induce nonspecific proliferation in T cells
(26–28 and Townsend, S.E., data not shown). Conversely,
experiments in TCR-transgenic mice involve unphysio-
logically high frequencies of specific T cells that can ob-
scure regulatory effects (29, 30). An elegant solution to the
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell receptor; HEL, hen egg
lysozyme; sHEL, soluble HEL; CFSE, 5- (and 6-) carboxyfluorescein di-
acetate succinimidyl ester.
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problem of tracking T cell fate in a physiological setting is
the adoptive transfer of TCR-transgenic T cells into intact,
unirradiated mice using unique cell surface markers to visu-
alize the subsequent responses of the T cells to antigen (31).
Here we show, using an adoptive transfer system, that
naive antigen-specific T cells efficiently find tolerant or na-
ive antigen-specific B cells in intact, unirradiated recipients,
in the context of a normal immune repertoire and an un-
perturbed microenvironment. Naive B cells that have acutely
captured antigen are helped to antibody production, whereas
tolerant B cells that have chronically captured antigen are
killed. In addition to direct presentation of antigen to T cells,
we describe a novel and efficient process of antigen transfer
by B cells to an endogenous APC population. In the absence
of adjuvant, presentation of antigen by tolerant B cells, na-
ive B cells, or after transfer of antigen to endogenous APCs
in each case leads to the initial activation and proliferation
of the T cells, followed by rapid disappearance.
 
Materials and Methods
 
Mice.
 
Transgenic mice expressing the hen egg lysozyme
(HEL)-specific 3A9 transgenic TCR (13) on the B10.BR back-
ground were bred with B6 Ly5
 
a
 
 congenic mice (gift of Dr. I.
Weissman, Stanford University, Stanford, CA) to generate TCR
 
1
 
Ly5
 
a
 
1
 
 H-2
 
kb
 
 donor mice. Transgenic mice expressing a HEL-spe-
cific BCR (Ig
 
HEL
 
) and double transgenic mice expressing both the
HEL-specific BCR and soluble HEL (sHEL 
 
3 
 
Ig
 
HEL
 
; reference
32) on the B6 background were bred with B10.BR mice to gen-
erate Ig
 
HEL
 
1
 
H-2
 
kb
 
 and sHEL
 
1
 
Ig
 
HEL
 
1
 
H-2
 
kb
 
 donor mice. Double
transgenic (sHEL 
 
3 
 
Ig
 
HEL
 
) mice bearing the 
 
lpr/lpr 
 
mutation in
Fas and expressing H-2
 
kb
 
 were bred and screened as described (7,
33). Recipient mice were unmanipulated (B10.BR 
 
3 
 
B6)F1
mice bred at the Research Animal Facility at Stanford (Stanford,
CA). The transgenic phenotypes of all donor cells were verified
by flow cytometry before transfer into recipient mice. Donor
cells and recipient mice were sex-matched for all transfers 
 
.
 
3 d.
Mice were used between 6 and 20 wk of age. Radiation bone
marrow chimeras were made as described previously (3, 4) using
T cell–depleted bone marrow from B6 donors to reconstitute le-
thally irradiated (B10.BR 
 
3 
 
B6)F1 recipients. The recipients
were left to reconstitute for 9 wk before use in experiments. Poly-
myxin B (110 mg/liter) and neomycin (1.1 g/liter) were added to
the drinking water weekly during reconstitution.
 
B Cell Purification and Antigen Loading.
 
Whole spleen cell sus-
pensions from B cell donors were transferred, except where indi-
cated in the figure legends. B cells were purified for some experi-
ments by incubating spleen cell suspensions with B220
 
1
 
 microbeads
(Milteny Biotec, Auburn, CA) as per the manufacturer’s instruc-
tions, and passing over MiniMACS columns (Milteny Biotec).
Preparations of whole spleen or purified B cells were loaded with
HEL in vitro by incubating cells at 
 
,
 
5 
 
3 
 
10
 
6 
 
cells/ml in RPMI
medium, 10% FCS, and 10 mM Hepes, with either 1 
 
m
 
g/ml
(Figs. 2 and 3) or 10 ng/ml (Figs. 1, 5, 6, and 7) HEL for 2 h at
37
 
8
 
C in polypropylene tubes. Cells were washed with complete
medium, counted, and resuspended in PBS for injection.
 
Western Blot for HEL Quantitation.
 
B cells were purified from
the spleens of HEL-specific Ig
 
HEL
 
-transgenic and double trans-
genic (sHEL 
 
3 
 
Ig
 
HEL
 
) mice and pulsed in vitro with 10 ng/ml HEL
as above. Cells were pelleted and lysed in 1% NP-40 under lysis
conditions previously described (34). Lysates of 3 
 
3 
 
10
 
6
 
 cells
were run on a 15% SDS–polyacrylamide gel under reducing con-
ditions. HEL was detected by probing with HyHEL9-biotin, fol-
lowed by Streptavidin–horseradish peroxidase (Nycomed Amer-
sham, Buckinghamshire, UK) and Renaissance detection system
(New England Nuclear Life Sciences, Boston, MA). Quantitation
was accomplished by adding titered amounts of exogenous HEL
(Sigma Chemical Co., St. Louis, MO) to nontransgenic spleen cell
lysates.
 
Adoptive Transfers.
 
Spleen, inguinal, brachial, axillary, cervi-
cal, and mesenteric lymph nodes were collected from 3A9 TCR
H-2
 
kb
 
 Ly5
 
a
 
 transgenic mice into RPMI medium plus 10% FCS,
and cell suspensions were prepared by mashing through metal
sieves. The cells were washed, counted, and resuspended in PBS
for injection. The transgenic phenotype of the cells was verified
by flow cytometry, the cells were pooled and cell suspensions
containing 2.5–3  
 
3 
 
 10
 
6
 
 CD4
 
1
 
 cells were injected intravenously
via the lateral tail vein. 18–24 h later, cell suspensions containing
2.5–3  
 
3 
 
 10
 
6
 
 HEL-specific transgenic B cells were injected intra-
venously via the lateral tail vein. Recipient mice were killed at
various time points after transfer, spleen, cervical lymph node,
and blood were collected, and cell suspensions prepared for anal-
ysis by flow cytometry and spot ELISA. At the time of collection,
fragments of spleen and inguinal lymph nodes were immersed in
OCT embedding medium (Tissue Tek; Sakura Finetek, Tor-
rance, CA) and flash frozen in liquid nitrogen for histology.
 
CFSE Labeling of T Cells.
 
Spleen and lymph node cells were
labeled with 5- (and 6-) carboxyfluorescein diacetate succinimidyl
ester (CFSE) as described (35). In brief, red blood cells were lysed
and the remaining cells were washed with PBS and then incu-
bated with 2 
 
m
 
M CFSE in PBS at 5 
 
3 
 
10
 
7
 
 cells/ml at 37
 
8
 
C for 30
min. The labeling was stopped by adding excess cold RPMI, 10%
FCS. The cells were washed with PBS, counted, and resuspended
in PBS for injection.
 
Flow Cytometry.
 
Flow cytometry was performed using FACS
 
Ò
 
440 and Vantage cytometers (Becton Dickinson, Mountain
View, CA) and FACS
 
Ò
 
-Desk and FLOJO analysis software (Stan-
ford Shared FACS
 
Ò
 
 Facility, Stanford, CA). The staining reagents
used were: Ly5
 
a
 
, AS-20–biotin or –PE; CD4, GK1.5-allophyco-
cyanin (gift of Dr. John Altman, Emory University, Atlanta, GA);
CD69-FITC or -biotin (PharMingen, San Diego, CA); B220,
RA3-6B2–PE (Caltag, Burlingame, CA); Streptavidin–Texas red
(TR; Vector Laboratories, Burlingame, CA), or –allophycocya-
nin (Biomeda, Foster City, CA); IgDa, AMS9.1-FITC; HEL,
HyHEL9-biotin or -Tricolor (custom conjugation; Caltag). Some
samples were live-gated on target populations to collect sufficient
data; all negative gating was performed after analysis, as described
in the figure legends.
 
Histology.
 
Cryostat sections (10 
 
m
 
M) of spleen were stained
for immunofluorescence using CD4-allophycocyanin and HEL fol-
lowed by HyHEL9-biotin and Streptavidin-Cy3 (Jackson Immu-
noresearch, Bar Harbor, ME) in the presence of normal mouse se-
rum, normal rat serum, and 0.1% bovine serum albumin. Images were
produced using a confocal microscope (Multiprobe 2010; Molecular
Dynamics, Eugene, OR), ImageSpace software (Molecular Dynam-
ics), and an Indigo 2 computer (Silicon Graphics, Palo Alto, CA) at
the Cell Sciences Imaging Facility, Stanford University (Stanford, CA).
 
Results
 
The experimental system used to visualize the conse-
quences of specific B–T cell interactions in vivo is dia- 
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grammed in Fig. 1 
 
A
 
. Lymph node and spleen cells were
isolated from 3A9 TCR-gene transgenic mice of (B6-Ly5
 
a
 
3 
 
B10.BR)F1 background (13) providing a source of Ly5
 
a
 
-
marked T cells specific for HEL peptide 46–61 bound to
I-A
 
k
 
. Approximately 3 
 
3 
 
10
 
7
 
 cells, which include 
 
z
 
3 
 
3
 
10
 
6
 
 HEL-specific CD4
 
1
 
 T cells, were transferred into nor-
mal congenic Ly5
 
b
 
 (B6 
 
3 
 
B10.BR)F1 recipients that had
not been immunized, irradiated, or treated in any way that
might change the lymphoid microenvironment or provide
adjuvant effects. The transferred cells were distinguished
from the excess of host cells by flow cytometry using anti-
bodies specific for allotypic markers particular to the trans-
ferred cells (Ly5
 
a
 
 for the transgenic T cells and IgD
 
a
 
 for the
transgenic B cells; Fig. 2). Flow cytometric analysis of the
recipient mice demonstrated that HEL-specific T cells were
seeded into the diverse immune repertoire at a low fre-
quency of 1 in 1,000–2,000 splenocytes (see below), allow-
ing us to track the cells and study their functions in a phys-
iologically relevant context.
One day after T cell transfer, naive B cells were isolated
from the spleens of Ig
 
HEL
 
 gene-transgenic mice, exposed to
intact HEL at 37
 
8
 
C in vitro for 2 h, and washed before
transferring 3 
 
3 
 
10
 
6
 
 cells into each of the T cell recipient
mice. The brief exposure to HEL in vitro loads the naive B
cells with antigen for presentation and activates them through
BCR signaling (data not shown). Alternatively, HEL-toler-
ant B cells were isolated from the spleens of sHEL/Ig
 
HEL
 
double transgenic mice, yielding a population that have
been chronically exposed to HEL so that they are loaded
with HEL peptides without becoming activated through
their BCR (36, 37). Flow cytometric analysis of the recipi-
ent mice demonstrated that HEL-specific B cells were also
seeded into the repertoire at a low frequency of 1 per
1,000–2,000 cells (see below).
In the recipient mice, small numbers of HEL-specific T
and B cells seed the white pulp of the spleen and migrate
effectively to the T cells zones and B cell follicles, respec-
tively (Fig. 1 
 
C
 
). The previously described TCR
 
1
 
 cells that
express neither CD4 nor CD8 (7, 13) did not traffic to the
lymphoid organs (data not shown). B cells that had been
exposed to HEL in vitro before transfer were preferentially
retained in the outer T cell zone, consistent with the previ-
ously described migration pattern for cells whose BCRs
have recently captured antigen and signaled (4, 5). The
amount of antigen that had been captured by the B cells
and transferred into the recipient mice was quantitated by
Western blot analysis of whole cell lysates of the antigen-
pulsed naive B cells and tolerant B cells (Fig. 1 
 
B
 
). Approx-
imately 2 ng of HEL is associated with the 3 
 
3 
 
10
 
6
 
 B cells
transferred to each mouse. This amount of antigen is 100–
100,000-fold lower than the dose of antigen previously
used to induce low-zone humoral tolerance (19, 20, 23,
38) or peripheral tolerance of CD4
 
1
 
 T cells in vivo (31,
39–41).
Despite the low frequency of transferred T and B cells,
the lack of adjuvant and irradiation, and the small amount
of antigen, HEL-pulsed naive B cells were helped to differ-
Figure 1. Tracking antigen-specific B cells and Ths in normal lym-
phoid tissue. (A) Schematic of experiments. (B) Quantitation of trans-
ferred antigen. NP-40 lysates of 3 3 106 antigen-pulsed, HEL-specific B
cells purified from naive (N) IgHEL-transgenic or -tolerant (T) HEL/IgHEL.
Double transgenic mice were subjected to SDS-PAGE, blotted to nitro-
cellulose, and probed with antibodies specific for HEL and actin as indi-
cated. Serial dilutions of HEL were added to nontransgenic spleen lysates
to give HEL titrations of 50 ng, 10 ng, 2 ng, and 400 pg. The amount of
HEL associated with each B cell population was z2 ng. (C) Transferred
T and B cells traffic to the T and B cell regions, respectively, of the
spleen. Three-color immunofluorescent analysis of spleen cryostat sec-
tions 12 h after transfer of sham-pulsed IgHEL transgenic B cells. Trans-
genic TCR1 lymph node and spleen cells were labeled with CFSE and
3 3 107 total cells containing 3 3 106 CD41 T cells were transferred into
intact (B10.BR 3 B6)F1 recipient mice, followed by IgHEL -transgenic
splenocytes (9  3 106 total cells containing 3 3 106 HEL-binding cells).
CFSE-labeled cells (red) localize to the white pulp. CD4-expressing cells
(blue) define the T cell zone. Colocalization analysis (ImageSpace soft-
ware; Molecular Dynamics) of CD4 and CFSE identifies the HEL-spe-
cific CD41CFSE1 cells (yellow; see also Fig. 3) within the T cell zone.
HEL-binding cells (green; HEL/HyHEL9-biotin/Streptavidin-Cy3) local-
ize to the white pulp outside the T cell zone. 
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entiate into antibody-forming cells by the HEL-specific
T cells (Fig. 2, 
 
A
 
 and 
 
B
 
). By 3 d after transfer, the HEL-
pulsed naive B cells lose surface IgD expression in the
presence, but not the absence, of HEL-specific T cells,
consistent with activation (Fig. 2 
 
A). By 5 d after transfer,
HEL-specific antibody-forming cells were readily detect-
able in the spleen in the presence, but not the absence, of
HEL-specific T cells (Fig. 2 B).
In contrast, tolerant B cells transferred under the same
conditions were killed by the rare HEL-specific T cells
within 5 d, but not by the excess of host T cells. Elimina-
tion of the tolerant B cells required B cell expression of the
Fas molecule, as Fas-deficient B cells homozygous the lpr
mutation were not killed (Fig. 2 C). This T cell–dependent
killing of tolerant B cells demonstrates that despite their
low frequency, the HEL-specific B and T cells interact effi-
ciently in the context of a normal immune system, and that
the outcome for tolerant B cells is identical to that found
previously in irradiated hosts where the cells are more fre-
quent and the microenvironment perturbed (7).
Because B–T cell interactions occurred efficiently under
these circumstances, we explored the consequences of these
interactions for the T cells in the recipients. 12 h after the
transfer of either HEL-pulsed naive B cells or HEL-tolerant
B cells, most of the HEL-specific T cells in the spleen had
been induced to express the early activation marker, CD69
(Fig. 3). T cell activation was antigen specific because CD69
expression was not induced on the endogenous T cells,
which are not HEL reactive (data not shown), nor on HEL-
reactive T cells transferred with sham-loaded HEL-specific
B cells. CD69 induction required the presence of HEL-
specific B cells, as depletion of B2201 splenocytes from
double transgenic sHEL/IgHEL donor inoculum eliminated
CD69 induction on the T cells, and HEL-pulsed nontrans-
genic B cells were not able to induce CD69 (data not
shown). Tolerant B cells selectively induced CD69 expres-
sion on lymph node T cells (Fig. 3), suggesting differences
in trafficking between recently activated and tolerant cells.
Very few CD69-expressing T cells were detectable in the
blood after transfer of either type of B cells, suggesting that
T cell activation may occur within the lymphoid organs.
Although HEL-specific B cells were required for activa-
tion of the T cells, this T cell activation was not solely due
to direct presentation of antigen by HEL-specific B cells,
Figure 2. Fate of B cells after T–B cell interactions in vivo. (A) Anti-
gen-pulsed, acutely activated B cells downregulate IgD in the presence of
transferred T cells. Transgenic Ly5a-marked T cells (3 3 107 total cells
containing 3 3 106 CD41 T cells) were transferred into intact recipient
mice, followed 24 h later by transfer of purified (94% B2201) acutely acti-
vated B cells that had been pulsed with 1 mg/ml HEL or sham pulsed for
2 h in vitro. 60 h after transfer, the surface phenotype of the transferred B
cells in the spleen was analyzed by flow cytometry using stains for HEL
binding, IgDa, and negative gating for CD4. Each plot is representative of
two or three individual recipients from each of three experiments. Similar
results were obtained using B cells pulsed with 10 ng/ml HEL. (B) Anti-
gen-pulsed, acutely activated B cells are helped by transferred T cells to
become antibody-forming cells. Transfer as in A, except that mice were
killed 5 d after B cell transfer. Antibody forming cells (AFC) in the spleen
were quantitated by spot ELISA (66). Data are representative of two sepa-
rate experiments. (C) Tolerant B cells are killed by transferred T cells via
Fas-mediated lysis. Transgenic T cells were transferred as in A and B, fol-
lowed by either wild-type or lpr/lpr-tolerant B cells (1.8  3 107 total cells
containing 3 3 106 HEL-binding cells). 60 h after B cell transfer, the
number of HEL-binding B cells in the spleen was analyzed by flow cy-
tometry, using stains for HEL binding, IgDa, and negative gating for
CD4. The background value in a mouse that received no transferred B
cells was zero. Dots, the number of HEL-binding B cells from the spleen
of an individual recipient mouse. These results are representative of four
separate experiments for the wild-type tolerant B cells, and two separate
experiments for the lpr/lpr-tolerant B cells.1615 Townsend and Goodnow
but also to transfer of antigen to another APC. We distin-
guished T cell–endogenous APC interactions from T–B
cell interactions by transferring antigen-pulsed IgHEL B cells
of the H-2bb MHC haplotype, which lack the I-Ak –pre-
senting element recognized by the HEL-specific TCR.
These B cells could not directly interact with HEL/I-Ak–
specific T cells, but were nevertheless able to induce com-
parable CD69 expression on the T cells in the spleen (Fig.
4). In contrast to the spleen, tolerant H-2bb B cells did not
induce CD69 expression by T cells in lymph node (Fig. 4),
raising the possibility that the endogenous APC responsible
for this very efficient presentation of antigen transferred
from B cells is resident in the spleen.
Proliferation of low frequency T cells in vivo was fol-
lowed using the fluorescent dye CFSE, which has been
shown to be diluted linearly with cell division in vivo (35).
Although the transferred T cells remained CFSE high in
the absence of antigen-pulsed B cells, many T cells became
CFSE low within 3 d after transfer with either HEL-loaded
naive or tolerant B cells (Fig. 5). The number of T cells
that had proliferated (CFSE low) and the number that had
not proliferated (CFSE high) were counted in each lym-
phoid tissue on days 3 and 5 after B cell transfer (Fig. 6). T
cell proliferation after transfer of tolerant B cells was fol-
lowed by disappearance of many of the CFSE low cells
Figure 3. Transfer of antigen-pulsed HEL-specific B cells or HEL-tolerant B cells induces the activation of most transferred HEL-specific CD41 T
cells in the spleen within 8 h. Transfer as in Fig. 2, except that mice were killed 8 h after B cell transfer and analyzed by flow cytometry for CD4, Ly5a,
and CD69, with negative gating for B220. The histograms represent CD69 staining on the small boxed CD41Ly5a1 population. The numbers indicate
the percentage of CD41Ly5a1 cells of total cells for each sample. The background values in a mouse that received no transferred T cells were 0.002% in
the spleen, 0.004% lymph node, and 0% in blood. Each plot is representative of two or three individual recipients from each of three experiments.
Figure 4. Activation of HEL-specific T cells in the spleen can be medi-
ated indirectly by transfer of antigen to host APCs. Transfer as in Fig. 2,
with the transfer of purified tolerant B cells (B2201 86–93%) expressing
MHC H-2kb or H-2bb. Mice were killed 12 h after B cell transfer and an-
alyzed for CD69 expression on T cells in spleen and lymph node as in Fig.
3. Light lines, CD69 expression by T cells in the absence of transferred B
cells; heavy lines, CD69 expression by T cells in the presence of transferred
B cells as indicated. Each plot is representative of one of two recipients in
each of two experiments. Similar CD69 expression by T cells was ob-
tained after transfer of acutely activated HEL-pulsed naive B cells express-
ing H-2bb in two additional experiments.1616 Abortive Proliferation of Rare T Cells In Vivo
from the spleen, the lymph node, and the blood by 5 d af-
ter transfer. Transfer of H-2bb–tolerant B cells resulted in a
similar degree of T cell proliferation and disappearance,
demonstrating that cross-presentation of antigen by endog-
enous APCs was sufficient to mediate the aborted prolifera-
tive response. Increasing the number of transferred tolerant
B cells did not decrease the number of remaining CFSE
high T cells, suggesting that the remaining cells may not be
capable of proliferation.
Surprisingly, HEL-pulsed naive B cells induced a com-
parable cycle of T cell proliferation and disappearance from
the spleen, lymph node, and blood (Figs. 5 and 7), despite
the fact that the acute antigen pulse triggers BCR signaling
and activates the naive B cells. In contrast, when HEL anti-
gen was given as a depot in adjuvant, the proliferating
CFSE low T cells did not disappear, but accumulated in
large numbers by day 5. Transfer of HEL-pulsed B cells
that lacked HEL-specific BCRs did not trigger T cell pro-
liferation or disappearance.
The data above showed that ultralow amounts of antigen
stimulated T cell proliferation and disappearance regardless
of whether acutely activated or tolerant B cells were the
source of antigen, and that cross-presentation of antigen
transferred from the B cells to endogenous APCs could
account for this aborted T cell response. To examine if di-
rect B–T cell interactions on their own could also trigger T
cell proliferation, we repeated the experiments in bone mar-
row chimeras that lack I-Ak on most host APCs, thus elim-
inating cross-presentation of antigen. For this purpose,
recipient mice were constructed by lethally irradiating
(B10.BR  3  B6)F1 mice (H-2kb) and reconstituting them
with parental B6 (H-2bb) bone marrow that had been T cell
depleted. The chimeric mice were held for 9 wk before use
in these experiments to allow time for the loss of labile or
radiosensitive H-2kb APCs and for the establishment of H-2bb
bone marrow–derived APCs. The recipient mice thus should
lack many I-Ak–expressing bone marrow–derived APCs,
but remain tolerant to H-2kb due to expression of H-2k on
radioresistant cells such as thymic epithelium.
Transfer of antigen-specific T cells with tolerant B cells
expressing H-2bb or H-2 kb into chimeric recipients [bb(®
kb)] showed that, under these circumstances, antigen pre-
sentation to the T cells depended upon B cells bearing
H-2k. Thus, HEL-specific T cells were not induced to ex-
press CD69 nor to proliferate after transfer of H-2bb–toler-
ant B cells in bb(® kb) chimeric recipients, whereas they
were triggered if the B cells expressed I-Ak–presenting
molecules (Fig. 8). The absence of T cell activation or pro-
liferation demonstrates that H-2bb–tolerant B cells do not
transfer antigen to residual I-Ak1 APCs for presentation to
T cells in these chimeras. Under these conditions, where
antigen presentation was limited to the HEL-tolerant B
cells, the T cells proliferated initially, but many of the pro-
liferated cells disappeared by 6 d after transfer. Thus, anti-
gen presented only by tolerant B cells was nevertheless suf-
ficient to drive T cell activation and proliferation in vivo.
The HEL-tolerant B cells were killed by the T cells as ef-
fectively as they were killed in conventional H-2kb recipi-
ents (data not shown), demonstrating that priming on en-
dogenous APCs is not required for this T cell effector
function. T–B cell interactions and T cell–endogenous
APC interactions induced apparently equivalent functional
outcomes in T cells under these noninflammatory condi-
tions in vivo.
Figure 5. Many HEL-specific
T cells have proliferated by 3 d
after transfer of either antigen-
pulsed HEL-specific or -tolerant
B cells. T and B cells were trans-
ferred as in Fig. 2, except that
TCR transgenic cells were la-
beled with CFSE before transfer.
Mice were killed 60 h after B
cell transfer, and CFSE fluores-
cence of CD41Ly5a1 splenocytes
analyzed by flow cytometry.
Each plot is representative of two
or three recipients in each of two
(HEL-pulsed naive B cells) or
four (tolerant B cells) separate
experiments.
Figure 6. T cells proliferate and disappear after transfer of tolerant B
cells. Transfer as in Figs. 2 and 5 with CFSE-labeled transgenic TCR1
cells and purified transgenic B cells (B2201 for all donor types 92–98%)
that were I-Ak1 (H-2kb) or I-Ak2 (H-2bb) and time points taken at days 3
and 5. Dots, the value from an individual recipient; bars, the mean value
for the group. Ig Tg, antigen-pulsed IgHEL-transgenic B cells; Dbl Tg, dou-
ble transgenic sHEL 3 IgHEL–tolerant B cells. One group of mice was in-
jected subcutaneously with 100 mg HEL emulsified in complete Freund’s
adjuvant (HEL/CFA) as a positive control for T cell proliferation. The
number of HEL-specific T cells was analyzed by flow cytometry and then
the number of CFSE high (above fluorescence channel 160) and CFSE
low (below fluorescence channel 160) were counted. The number of
HEL-specific T cells per 105 cells for each individual was normalized to
the number of nonspecific CFSE high B cells for that individual divided
by the average number of nonspecific CFSE high B cells in order to cor-
rect for any small differences in injection efficiency between different re-
cipients.1617 Townsend and Goodnow
Discussion
The results presented here demonstrate that B cell pre-
sentation of antigen to T cells can have profound effects on
T cell fate in vivo, and that, together with a novel mecha-
nism of antigen transfer to endogenous APCs, such antigen
presentation may be important in limiting T cell responses
to antigen in the absence of inflammation. Infrequent anti-
gen-specific T and B cells efficiently find each other in in-
tact recipients, in the absence of inflammation, and in the
context of a normal immune repertoire, unperturbed mi-
croenvironment, and trace amounts of antigen. The conse-
quences of these interactions differ for acutely activated na-
ive B cells and tolerant B cells, such that the T cells help
the naive B cells to become antibody-forming cells, whereas
the T cells kill the tolerant B cells. In marked contrast with
in vitro experiments, these direct interactions with acutely
activated or tolerant B cells do not have distinct effects on
T cell fate in vivo. Both direct presentation by B cells and
indirect presentation by endogenous APCs induce abortive
proliferation of T cells. This effect on T cells results from
very efficient presentation of minute quantities of antigen.
The process of concentration and presentation of such
small quantities of antigen may be important in establishing
or maintaining low zone tolerance, in epitope spreading
during disease, and in maintaining tolerance to potential al-
lergens.
Minute quantities of antigen (z2 ng) are transferred by
B cells into recipient mice in these experiments. This small
amount of antigen is nevertheless efficiently transferred to
and presented by endogenous APCs. Transfer of H-2bb B
cells activated T cells in the spleen, which suggests that B
cell–bound antigen is transferred to endogenous I-Ak–ex-
pressing APCs that then present antigen to T cells. In con-
trast to the spleen, tolerant H-2bb B cells do not induce
CD69 expression by T cells in lymph node (Fig. 4). The
efficient cross-presentation of transferred antigen by endog-
enous APCs in the spleen and not the lymph node, as well
as the lack of CD69 expression by T cells in the blood,
raises the possibility that the responsible APC is resident in
the spleen, rather than one that acquires antigen in the pe-
riphery and migrates through the blood to the spleen or
through the lymph to the lymph nodes. The essential prop-
erty of the endogenous APC may be the ability to receive
and present transferred antigen with high efficiency, a
property that may be linked to its location in a particular
splenic microenvironment. We are actively investigating
the mechanism of antigen transfer from antigen-specific B
Figure 7. HEL-specific T cells disappear to the same degree after trans-
fer of antigen-pulsed B cells, tolerant B cells, or excess tolerant B cells.
Transfer as in Fig. 2 using CFSE-labeled transgenic TCR1 cells and un-
purified splenocytes from B cell donors. Dots, the number of HEL-spe-
cific T cells of each phenotype from an individual recipient; bars, the
mean value for the group. Ig Tg, antigen-pulsed IgHEL-transgenic B cells;
Dbl Tg, double transgenic tolerant B cells. One group of mice was in-
jected subcutaneously with 100 mg HEL emulsified in RIBI adjuvant
(HEL/RIBI) as a positive control for T cell proliferation. Values are flow
cytometric data analyzed as in Fig. 6.
Figure 8. HEL-specific T cells are activated, proliferate, and disappear
after direct interaction with tolerant B cells. (A) Expression of CD69 by
HEL-specific T cells from the spleen 24 h after B cell transfer showing
that antigen presentation is limited to HEL-specific B cells in the chimeric
mice. Transfer as in Fig. 6 using CFSE-labeled transgenic TCR1 cells and
double transgenic sHEL 3 IgHEL splenocytes containing HEL-tolerant B
cells expressing either MHC H-2kb (kb) or H-2bb (bb). The recipient mice
were either intact (B10.BR 3 B6)F1 mice (H-2kb) expressing I-Ak on en-
dogenous APCs (kb), or were I-Ak–deficient bone marrow chimeras
[bb(® kb)] constructed by reconstituting lethally irradiated (B10.BR 3
B6)F1 mice with B6 T cell–depleted bone marrow. The chimeras were
used 9 wk after reconstitution when many of the original B cells and my-
eloid APCs would be expected to have been replaced by new H-2bb cells
from the donor marrow. (B) Proliferation and disappearance of HEL-spe-
cific T cells. Dots, the number of HEL-specific T cells of each phenotype
from an individual recipient; bars, the mean value for the group. Values
are flow cytometric data analyzed as in Fig. 6, except that values were not
normalized for injection efficiency, as there was some variation in non-
specific CFSE1 B cell frequency among the chimeric recipients, probably
due to incomplete tolerance to B cell antigens in the context of H-2kb.1618 Abortive Proliferation of Rare T Cells In Vivo
cells to endogenous APCs, which could be antibody medi-
ated, such as Fc receptor or complement receptor uptake of
antigen–antibody complexes, or cell mediated, such as phago-
cytosis of whole cells. We have identified the endogenous
APC that receives antigen transferred from B cells as a la-
bile or radiation-sensitive cell that is probably bone marrow
derived, as cross presentation did not occur in radiation
chimeras where bone marrow–derived cells lacked the rel-
evant restriction element, I-Ak. Interestingly, cultured my-
eloid dendritic cells are not capable of T cell stimulation by
re-presentation of transferred antigen from HEL-specific B
cells in vitro, which suggests that neither immature nor
mature activated dendritic cells mediate this activity (data
not shown). Candidate APCs are marginal zone macrophages
(42), migratory dendritic cells located in the bridging chan-
nels between the B cell follicles of the spleen (43), and lym-
phoid dendritic cells located in the T cell zone (44).
Studies in B cell–deficient mice demonstrate that B cells
are not essential for the induction of peripheral T cell toler-
ance to some superantigens (45), the injection of micro-
gram quantities of peptide (45), or microgram or milligram
quantities of intact antigen (46, 47). These models rely on
high doses of antigen that could load many types of APCs,
obscuring a role for specific B cells in peripheral T cell tol-
erance. The one model that addressed T cell tolerance in
the presence of low serum levels of antigen (.0.5 ng/ml)
did not exclude a role for thymic deletion in the observed
tolerance (47). B cells may be necessary for the mainte-
nance of T cell tolerance in nonobese diabetic (NOD)
mice (48) and can induce tolerance in vivo (17–22). The
results presented here demonstrate that the mechanism of B
cell tolerogenicity could be the induction of T cell abortive
proliferation either by direct presentation of antigen or by
transfer of antigen to an endogenous APCs.
Previous studies have shown that the activation state of B
cells is critical for the activation of T cells in vitro, such that
antigen-specific, activated B cells are effective APCs (12),
whereas as unspecific, resting B cells are not (12, 49). Naive
HEL-specific B cells are induced to express high levels of
the costimulatory molecule B7.2 upon HEL exposure,
whereas HEL-tolerant B cells are deficient in their ability
to upregulate B7.2 (37, 50). As a result of differences in
B7.2, antigen-activated B cells, but not tolerant B cells, in-
duce 3A9 TCR-transgenic cells to proliferate and secrete
cytokines in vitro (13). Surprisingly, both tolerant and acti-
vated HEL-specific B cells induce abortive proliferation in
T cells in vivo (Figs. 5 and 7). This difference in B7.2 ex-
pression by the B cells does not seem to affect the initial
proliferation of T cells in vivo, even when antigen is only
presented by the tolerant B cells in the bb(® kb) chimeric
recipients. The initial proliferation of T cells in vivo may
either be B7/CD28 independent or bystander APCs may
provide this costimulation in trans, even when they cannot
present the antigen. A similar, initial proliferative burst has
been noted in response to peptides or superantigens in
CD282/2 mice (51, 52) supporting the notion that this de-
fault pathway of abortive proliferation is CD28 indepen-
dent. It is intriguing that antigen-exposed naive B cells and
tolerant B cells induce an equivalent T cell abortive prolif-
erative response in vivo despite eliciting distinct T effector
functions (help versus killing). We are currently testing
whether interaction with activated and tolerant B cells in-
duces different cytokine expression by the T cells.
In these experiments, minute quantities of antigen asso-
ciated with rare antigen-specific B cells elicited a profound
effect on rare antigen-specific T cells. This approach con-
trasts with those used previously in which large quantities
of antigen or superantigens were injected (22, 31, 39, 53–
57) often into mice containing very high frequencies of an-
tigen-specific T cells. The proliferation followed by disap-
pearance over a 5-d time course that is induced by these
small quanta of antigen is nevertheless remarkably similar to
what has been observed in the high antigen dose models
(31, 51–53, 57). The similarity between our findings using
these small quanta of antigen and the previous observations
using much higher doses of antigen suggest that abortive
proliferation of T cells is a default mechanism for initial T
cell responses to antigen. Factors that dictate whether a
proliferative response will be sustained, such as TNF or
other adjuvant effects, may be additive to this initial default
response of abortive proliferation (55).
It seems counterintuitive that a response as potentially
dangerous as T cell proliferation would be “hard wired” as
a default response. The key controlling factor must be an
equally hard-wired default disappearance mechanism, which
prevents T cells from sustaining exponential proliferation.
A likely candidate mechanism is activation-induced cell
death (AICD), a Fas-mediated T cell suicide mechanism
that has been shown to limit T cell proliferation in vitro
and in vivo (58–62). Activated T cells express both Fas and
Fas ligand, and can kill themselves by Fas-mediated lysis.
The control of abortive versus sustained proliferation of T
cells may be critical for the maintenance of peripheral self-
tolerance. The disappearance of T cells after B cell transfer
is likely to be tolerogenic, by the reduction in T cell pre-
cursor frequency. In continuing experiments, we are test-
ing whether the disappearance is Fas mediated and whether
the remaining T cells have been functionally inactivated.
B cells represent a potential threat to the maintenance of
self-tolerance because of their well-characterized ability to
concentrate a unique subset of antigens determined by their
BCR specificity and to present these antigens to T cells (9,
10). Self-reactive B cells can present self-antigen to self-
reactive T cells and so initiate autoimmune responses or con-
tribute to epitope spreading (63, 64). Similarly, high affinity
memory B cells located in the sites of antigen entry to the
mucosa and the lymphoid organs concentrate antigens, mi-
grate to T zones, and there initiate or amplify immune re-
sponses, which may include allergic responses to nonpatho-
genic antigens (1, 2). The physiological relevance of these
phenomena is highlighted by the presence of autoreactive
B cells in the T cell zones in autoimmune MLR/lpr mice
(65) and the association of the presence of B cells with the
initiation of diabetes in nonobese diabetic mice (48). T cell1619 Townsend and Goodnow
abortive proliferation after encounter with antigen concen-
trated by B cells may provide a regulatory checkpoint that
limits the effects of antigen presentation in the absence of
inflammation, and bypassing this checkpoint may result in
pathogenic T cell responses in allergy and autoimmunity.
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